1. Scrip
  2. >>Business
  3. >>Earnings

Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain

Q4 Sales Edge Past Consensus

 
• By Ayisha Sharma

Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.    

Pair of feet on blue weighing scales, obesity concept
Novo's Wegovy Is A Blockbuster Product For Obesity • Source: Shutterstock

Novo Nordisk A/S’s weight loss drug Wegovy (semaglutide) has successfully emerged from its supply issues, but supply constraints will continue to be an issue for the firm as its shifts its R&D focus beyond its GLP-1 franchise.

Despite these troubles, Novo’s full-year 2022 sales increased by 26% in local currencies to DKK177bn ($17.14bn) while Q4 sales rose by 25% to DKK48.09bn, beating analyst consensus estimates of DKK47.27bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.